Endocrine Abstracts

Introduction: The pituitary tumors which are considered pituitary incidentalomas are accidentally discovered at pituitary scan and they associate a lack of pituitary hyper-secretion. Opposite to what generally are considered for adrenal incidentalomas, the pituitary incidentalomas are more frequent with years of life.Aim: We analyzed the incidentaloma sizes related to decades of age.Material and method: This is a retrospective stud...

Material-Method: We registered from February 26, 2020 until January 23, 2022 (almost 2 years) patients with chronic autoimmune thyroiditis Hashimoto. Usual parameters for this disease were investigated: age, sex, ATPO, FT4, TSH, ultrasound pattern, antibody evolution, immune associations, lost pregnancies, other clinical associations (alergies, breast cancer). Patients were divided into 2 groups: those who had covid-19 (C-19) vs. those who did not have viral disease (<u...

Aim: Re-analyzing (study starting in 2007) the effect of injectable testosterone undecanoat depot (TUD) in hypogonadic patients.Materials and Methods: A. Patients: at onset 231 men with hypogonadism (median: 62 y). B. Distribution: by decade (starting with 20y); no =4, 14, 24, 61, 63, 49, 17, 1. C. TUD (NebidoR-Bayer) 1000 mg injected one/3 months i.m. D. Prostate volume (PV) appreciated by per-abdominal ultrasound: 3.5–5 MHz probe, ellip...

Aim: Most research teams analyze the evolution of patients with Hashimoto thyroiditis (HT) on syndromic basis (e.g., the thyroid function), not on pathogenic basis (the autoantibodies). Thus, most researchers refer to thyroid hormone evolution. In this study we re-analyzed (first in 2018) how evolve the antithyroid autoantibodies. Therefore, we analyzed the antithyroperoxydase antibodies (ATPO) evolutive patterns in patients with HT.Method: 1. ATPO level...

Aim: To find if testosterone undecanoat 1000 mg injection (Nebido; Bayer-Schering) has a negative effect on prostate.Materials and methods: i) PSA (ng/ml) was registred retrospective (from files) and prospective analysis (onset 2010). ii) From over 175 patients to whom testosterone undecanoate 1000 mg, i.m. was administrated at 3 months, in the last 4 years, and to whom the prostatic volume was quantified (Journal of Sexual Medicine8</st...

Objectives: The study of the real indications for thyroid ultrasound and in which pathological conditions the echography is of real use and not for abuse.Material and methods: In the last 10 years, over 13 000 echographies were performed in 5136 consecutive patients for ‘thyroid disturbances’. In a previous paper we described 7 echographic patterns for thyroid ultrasound (9th ECE). The diagnosis of Hashimoto’s thyroiditis (HT) was consider...

Introduction: The prevalence of autoimmune disorders (AID) is more frequent in patients with Hashimoto’s thyroiditis (HT).Aim: To see if the clinical and biochemical aspects are different among the patients with HT and if they change related to the systemic or organ specific AID.Material and method: A. HT was diagnosed on antithyroperoxidase antibodies (ATPO) over 34 UI/ml. B. 491 patients with HT were investigat...

Objectives: To analyze the conceptual frame for a correlation between thyroid echographic description and antithyroid peroxydase antibodies (ATPO) levels in Hashimoto’s thyroiditis (HT).Material-methods: A. 783 patients: 396 with HT (ATPO>34 UI/ml), 386-control (ATPO<34 UI/ml). B. Ultrasound aspects were described in 8 patterns: 0-thyroid lack; 1 – hypoechogenic and pseudonodular; 2 – hypoechogenic and homogenous; 3 &...

Aim: Has testosterone undecanoat 1000 mg intramuscular injection (NebidoR; Bayer), 1 at 3month, negative effect on prostate? For this purpose, we appreciate the prostatic volume (see Pisoschi, this congress) and PSA (this study) in hypogonadic patients after testosterone injection up to 11 years.Material and method: A. PSA (ng/ml) was done in Bucharest accredited laboratories.B. Patients: PSA analysis was done before tre...

Aim: Re-Analysing (study starting in 2007) the effect of injectable testosterone undecanoat depot (TUD) in hypogonadic patients.Material-method: A. Patients: at onset 278 men with hypogonadism (median: 61 y).B. Distribution: by decade (starting with 20y); no =6, 17, 25, 70, 86, 55, 18, 1.C. TUD (NebidoR-Bayer) 1000 mg injected one/3 months i.m.D. Prostate volume (PV) apprecia...